If Zoetis’s dermatology portfolio continues to witness robust demand trends in …
Of the companies Carr covers, Theravance could attract big pharmas like Amgen (AMGN), Eli Lilly (LLY) and Teva Pharmaceutical (TEVA ... Head to IBD Data …
There were quite a few important developments this week with Eli Lilly and …
Eli Lilly and Co. (NYSE: LLY) was reiterated as Buy and the price target was raised ... The shares were last seen trading up almost 2% at $44.00, in a 52-week high of $44.84. This stock was trading at about $37 in August prior to the two …
Eli Lilly (LLY), a steady grower if there ever was one, just went bonkers to the upside. The stock is up some 16% in the past month, which is quite uncharacteristic given its typical demeanor. Longtime followers of the medical space may …
Eli Lilly And Co (NYSE:LLY) is having an incredibly rough day in the market today. After starting the day off in the red, the stock has fallen further and further throughout the day. Below, we’ll talk about what we’re seeing from the stock, why, …
However, the lackluster performance of LLY stock should change soon, according to analysts at Goldman Sachs. (See also: Eli Lilly President/CEO to Retire at Year's End.) A team of Goldman Sachs analyst led by Jami Rubin said in a …
Jim Cramer highlighted Eli Lilly (NYSE: LLY) on last night's Mad Money, calling it a stock that will help investors sleep at night given its 5.2% dividend yield. Interestingly, Cramer said he believes that Eli Lilly's stock has just recently bottomed.
The Eli Lilly stock price today (Wednesday) fell as much as 4.8% after the company released new trial results on its Alzheimer's drug solanezumab. Eli Lilly and Co. (NYSE: LLY) officials released data from a follow-up study on two of …
Eli Lilly & Co. LLY, -0.76% shares dropped 5.5% and Incyte Corp. INCY ... 0.18% Read the full story: Apple stock still has room to rise after recent highs, analysts say